ACR responses: (A) responses at Week 52 and Week 104

Slides:



Advertisements
Similar presentations
Monthly improvements in paid work productivity: ankylosing spondylitis (AS) and non-radiographic axial spondyloarthritis (nr-axSpA) subpopulations (employed.
Advertisements

Monthly improvements in family, social and leisure activities to week 96 (last observation carried forward imputation). Assessed using the arthritis-specific.
Monthly improvements in paid work productivity: overall axial spondyloarthritis population (employed patients only; last observation carried forward imputation). Assessed.
PASI responder rates (A, B) and total resolution in (C) nail psoriasis, (D) enthesitis and (E) dactylitis in affected patients receiving CZP from Week.
Change in mean extent of lung tissue and lung tissue with ground glass or reticular pattern involvement from baseline to 12 months follow-up in patients.
ACR20, ACR50, and ACR70 response rates during the 12-week study of Japanese patients with rheumatoid arthritis treated with baricitinib or placebo. ACR20,
Patients included in linear extrapolation and observed/last observation carried forward analyses at week 48. Patients who were rescued or discontinued.
Naïve B cells (CD19+CD27-), memory B cells (CD19+CD27+) and plasmablasts (PB CD27++) levels in patients with systemic sclerosis. Indicated points resemble.
Percentage of patients achieving EULAR response
ASAS 20/40 response rates, and mean change from baseline in BASDAI through week 156* of treatment. *For patients who discontinued, the end of treatment.
Baseline scores and corresponding changes to week 96 of the RAPID-axSpA trial for all CZP-treated patients included in the imaging substudy for: (A) SPARCC.
Flow diagram of the literature search process, including exclusions and reasons for exclusions. *Population of pregnant women (n=2), asymptomatic antiphospholipid.
Odds ratios for achieving ACR50 response, ACR70 response, DAS28-CRP LDA, DAS28-CRP remission and CDAI LDA at weeks 12 and 24. High, >median value in overall.
Improvement in PROs, TJC, SJC and PGA at month 6 in patients achieving (A) ACR50, (B) CDAI LDA and (C) HAQ-DI
Clinical and patient-reported outcomes for patients randomised to CZP 200 mg Q2W and CZP 400 mg Q4W to week 96. Clinical and patient-reported outcomes.
Patient disposition through 48 weeks in RA-BEYOND
Mean concentrations (mM) of PG1+2, PG3 and PG4+5 in patients with or without MTX-related toxicity at baseline, week 4 and week 24/26 in (A) CONCERTO and.
ASAS 20/40 responses in anti-TNF-naïve and anti-TNF-IR subjects at weeks 52, 104 and 156. ASAS 20/40 responses in anti-TNF-naïve and anti-TNF-IR subjects.
Frequency of patients in flare at each time point over 3 months
Disease activities evaluated as a comparison between abatacept plus MTX and placebo plus MTX groups. Disease activities evaluated as a comparison between.
Schematic presentation of enrichment through linkages of clinical Rheumatology register data to other national data sources within each of the five Nordic.
HAQ-DI change from baseline and proportion of patients achieving MCID after 24 weeks in patients treated with PBO, IXEQ4W or IXEQ2W alone or in combination.
ACR response rates at 24 weeks in patients treated with PBO, IXEQ4W or IXEQ2W alone or in combination with cDMARDs or MTX. The proportions of patients.
Resolution of tophi after exposure to pegloticase.
ACR responder rates in patients receiving CZP from Week 0, stratified by prior anti-TNF exposure (A−C) and the proportion of patients receiving CZP from.
The severity of fatigue over 8 years of disease in early rheumatoid arthritis patients. The severity of fatigue over 8 years of disease in early rheumatoid.
Efficacy outcomes in patients aged ≥65 years versus younger patients: ACR outcomes at (A) week 12 and (B) week 24. Efficacy outcomes in patients aged ≥65.
Patient-reported outcomes: proportion of patients with clinically meaningful improvements in (A) SF-36 PCS and MCS at Week 52 and Week 104*†‡ and (B) HAQ-DI.
Treatment strategy. Treatment strategy. For every patient, changes of treatment were analysed per change, for up to five subsequent therapeutic changes.
Difference in the risk of MACEs in patients treated with anti–IL17 agents compared with the placebo in RCTs. IL,interleukin; MACEs, major adverse cardiovascular.
Matrix risk model showing the probability of SRP in patients with moderate disease activity after 3 years of MTX treatment. Matrix risk model showing the.
Multivariate analysis for SRP after 3 years in patients with moderate disease activity despite MTX treatment. Multivariate analysis for SRP after 3 years.
Clinical response in patients with early and established RA at month 24. *p
Least squares mean (LSM) changes from baseline in (A) Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue) Total score and (B) Ankylosing.
Improvement in PROs, TJC, SJC and PGA at month 6 in patients achieving (A) ACR70, (B) CDAI REM and (C) SDAI REM. For tofacitinib 5 and 10 mg BID treatment.
(A–D). (A–D). B-cell and Ig changes. Mean changes in total CD3-CD20+ B-cells (A) and immunoglobulin (Ig) subclasses levels (B-D) were measured over 24 weeks.
Difference in the risk of MACEs in patients treated with anti-IL23 agents compared with the placebo in RCTs. IL, interleukin; MACEs, major adverse cardiovascular.
Improvement in FACIT-F fatigue score according to ACR20 response status (ACR, American College of Rheumatology; DMARD, disease-modifying antirheumatic.
Percentage of patients with RA achieving DAS28(CRP)<2
ACR20 response rates. ACR20 response rates. ACR20 response rates based on non-responder imputation (NRI) for the 120/Q4W, 90/Q2W and placebo groups over.
Joint damage progression evaluated as a comparison between abatacept plus MTX (grey bar) and placebo plus MTX groups (open bar). Joint damage progression.
Radiographic endpoints: (A) change from baseline in SHS at Week 52 and Week 104*†; (B) probability plots of change from baseline in SHS at Week 52 and.
Relative treatment effects concerning efficacy endpoints in patients with inadequate response to methotrexate for triple therapy versus TNFi–methotrexate.
Rates of ACR50 response and prespecified MTX-related adverse events in patients in the (A) CONCERTO study over 26 weeks and (B) MUSICA study over 24 weeks. ACR50, American.
Employment of patients with AS compared with controls, by BASDAI
ACR20/50/70 response rates at week 24 (TP1 per-protocol set).
Percentage of patients in each treatment group whose biomarker values returned to normal reference ranges at week 24. Percentage of patients in each treatment.
Percentage of patients achieving 20% improvement in the American College of Rheumatology criteria at week 12 by patient demographic and disease characteristics.
Percentage of responders at month 6 by (A) ACR50, SDAI/CDAI LDA, and HAQ-DI
Monthly improvements in home productivity: ankylosing spondylitis (AS) and non-radiographic axial spondyloarthritis (nr-axSpA) subpopulations (last observation.
Frequency of methotrexate (MTX) doses at 24 months (plot) and summary of MTX doses across the MTX dosing categories (low, medium, high) based on data at.
Subject disposition through week 156 of treatment
Patient disposition after 2 years of treatment.
Difference in the risk of MACEs in patients treated with anti-TNF agents compared with the placebo in RCTs. MACEs, major adverse cardiovascular events;
Satisfaction with control of RA
The proportions (and 95% CIs) of anti-CCP+/RF+, anti-CCP+/RF-, anti-CCP-/RF+ and anti-CCP-/RF- patients receiving tofacitinib 5 or 10 mg two times a day.
Achievement of MDA over 144 weeks in patients initially receiving adalimumab or placebo during the double-blind period. Achievement of MDA over 144 weeks.
Classification tree with the selected characteristics.
Design for the long-term extension study RA-BEYOND from randomisation in the originating studies. Design for the long-term extension study RA-BEYOND from.
Sera metabolite profiles of patients with RA discriminate rituximab responders and non-responders. Sera metabolite profiles of patients with RA discriminate.
Patient-level radiographic progression of structural joint damage at year 1 and year 2 by original randomisation. Patient-level radiographic progression.
Kaplan-Meier estimate of drug continuation until discontinuation for tocilizumab, canakinumab, anakinra and etanercept, as a first biological agent for.
Multivariable model of adjusted
Percent of patients with ASDAS inactive disease grouped by normal or elevated CRP at baseline through week 156. §p
Improvement in BASDAI score in patients with normal or elevated CRP at baseline through week 156. *p
ACR20, ACR20 and ACR70 response rates (proportions of patients meeting ACR 20, 50% or 70% improvement criteria) in patients with rheumatoid arthritis randomised.
MRI remission in the imaging set of patients from the RAPID-axSpA trial. MRI remission in the imaging set of patients from the RAPID-axSpA trial. Remission.
Changes in non-classical (CD11b+CD14+CD163−CD16+) and classical (CD11b+CD14+CD163+CD16−) monocytes over time in patients with rheumatoid arthritis (RA)
ACR20 (A), ACR50 (B) and MDA (C) response rates at 24 weeks in patients treated with PBO, IXEQ4W or IXEQ2W alone or when added to background cDMARDs or.
Distribution of points (%) across the ESSDAI domains in patients with neurological involvement and in those with non-neurological systemic involvement.
Presentation transcript:

ACR responses: (A) responses at Week 52 and Week 104 ACR responses: (A) responses at Week 52 and Week 104*†‡; (B) maintenance of response from Week 52 to Week 104§. *n values shown in legend are the number of patients evaluable at Week 52. ACR responses: (A) responses at Week 52 and Week 104*†‡; (B) maintenance of response from Week 52 to Week 104§. *n values shown in legend are the number of patients evaluable at Week 52. Responses at Week 52 included EE/LE and CO patients. †For ACR20 and ACR90, placebo to Sir 50 mg q4w, n=225; placebo to Sir 100 mg q2w, n=232; Sir 50 mg q4w, n=475; Sir 100 mg q2w, n=468. ‡ACR response was based on imputed value by missing data (NR)/TF(NR). §ACR response was based on observed data. ACR20/ACR50/ACR70/ACR90, American College of Rheumatology 20%/50%/70%/90% response; CO, crossover; EE, early escape; LE, late escape; NR, non-responder; Sir, sirukumab; TF, treatment failure; q2w, every 2 weeks; q4w, every 4 weeks. Carter Thorne et al. RMD Open 2018;4:e000731 Copyright © BMJ Publishing Group & EULAR. All rights reserved.